12/1
06:03 pm
gral
GRAIL (NASDAQ:GRAL) was given a new $110.00 price target on by analysts at Morgan Stanley.
Low
Report
GRAIL (NASDAQ:GRAL) was given a new $110.00 price target on by analysts at Morgan Stanley.
12/1
04:01 pm
gral
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/18
04:02 pm
gral
GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference
Medium
Report
GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference
11/17
08:45 am
gral
GRAIL (NASDAQ:GRAL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $85.00 to $105.00. They now have a "buy" rating on the stock.
Medium
Report
GRAIL (NASDAQ:GRAL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $85.00 to $105.00. They now have a "buy" rating on the stock.
11/13
01:00 pm
gral
Grail Q3 Earnings: Massive Stock Gains, Mediocre Performance - I'm Still Not Sold [Seeking Alpha]
Medium
Report
Grail Q3 Earnings: Massive Stock Gains, Mediocre Performance - I'm Still Not Sold [Seeking Alpha]
11/12
04:02 pm
gral
GRAIL Reports Third Quarter 2025 Financial Results
Medium
Report
GRAIL Reports Third Quarter 2025 Financial Results
11/12
08:05 am
gral
GRAIL (NASDAQ:GRAL) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.
Low
Report
GRAIL (NASDAQ:GRAL) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.
11/4
04:02 pm
gral
GRAIL to Present at 7th Annual Wolfe Research Healthcare Conference
Medium
Report
GRAIL to Present at 7th Annual Wolfe Research Healthcare Conference
10/29
04:02 pm
gral
GRAIL to Announce Third Quarter 2025 Financial Results
Medium
Report
GRAIL to Announce Third Quarter 2025 Financial Results
10/22
10:26 am
gral
GRAIL (NASDAQ:GRAL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $75.00 to $85.00. They now have a "buy" rating on the stock.
Low
Report
GRAIL (NASDAQ:GRAL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $75.00 to $85.00. They now have a "buy" rating on the stock.
10/20
06:30 am
gral
GRAIL, Inc. Announces $325.0 Million Private Placement Financing
Medium
Report
GRAIL, Inc. Announces $325.0 Million Private Placement Financing
10/20
06:00 am
gral
GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)
Medium
Report
GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)
10/17
06:08 pm
gral
GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
High
Report
GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
10/16
08:22 am
gral
Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia
High
Report
Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia
10/6
10:17 am
gral
Liquid Biopsy for Early Cancer Detection and Monitoring Market Report 2025-2033, with Profiles of GRAIL, AnchorDx, Burning Rock Biotech, Genecast, Guardant Health, Elypta, Freenome, and Oncimmune [Yahoo! Finance]
Low
Report
Liquid Biopsy for Early Cancer Detection and Monitoring Market Report 2025-2033, with Profiles of GRAIL, AnchorDx, Burning Rock Biotech, Genecast, Guardant Health, Elypta, Freenome, and Oncimmune [Yahoo! Finance]
10/3
11:11 am
gral
GRAIL (NASDAQ:GRAL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $43.00 to $75.00. They now have a "buy" rating on the stock.
Medium
Report
GRAIL (NASDAQ:GRAL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $43.00 to $75.00. They now have a "buy" rating on the stock.
10/3
09:03 am
gral
GRAIL (NASDAQ:GRAL) was given a new $75.00 price target on by analysts at UBS Group AG.
Low
Report
GRAIL (NASDAQ:GRAL) was given a new $75.00 price target on by analysts at UBS Group AG.
9/23
09:01 am
gral
GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC
Low
Report
GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC
9/10
04:02 pm
gral
GRAIL to Present at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
Medium
Report
GRAIL to Present at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum